NeoGenomics falls after Q1 sales miss

Cancer testing services firm NeoGenomics' NEO.O shares fall 3.6% to $9.61 premarket

Company reports Q1 revenue of $168 million, missing analysts' estimates of $171 million, according to data compiled by LSEG

But company raises its annual revenue forecast to be between $747 million and $759 million, up from previous range of $735 million to $745 million

Separately, company says it is collaborating with biotech firm Ultima Genomics to expand clinical test offerings for cancer patients using Ultima's sequencing platform designed for large-scale genomic studies

As of last close, NEO has fallen 39.5% YTD